AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and ...

AstraZeneca PLC closed 24.38% short of its 52-week high of £133.88, which the company reached on September 3rd.

CEO Pascal Soriot said Europe was "falling behind" in attracting investment and needed to "invest more in what really matters ...

Soliris (eculizumab) was first approved for paroxysmal nocturnal hemoglobinuria (PNH) in 2007 under Alexion, which later became AstraZeneca’s rare disease unit after its $39 billion buyout in 2020.

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

It does not necessarily reflect the view of The Herald. A group of AstraZeneca staff members have donated toys to the children's ward at Macclesfield General Hospital. The group, made up of Sanjay ...

At close: April 17 at 12:59:35 PM GMT+2 ...

A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder drug by blocking competitors that wanted to launch similar, less-expensive ...